Comparative Pharmacology
Head-to-head clinical analysis: CEFOTAXIME versus TAZIDIME.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFOTAXIME versus TAZIDIME.
CEFOTAXIME vs TAZIDIME
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefotaxime inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation, and activating autolytic enzymes.
Ceftazidime inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and disrupting peptidoglycan cross-linking.
1-2 g IV every 6-8 hours; maximum 12 g/day. For uncomplicated infections: 1 g IV every 8-12 hours.
1 to 2 g IV/IM every 8 hours; maximum 6 g/day.
None Documented
None Documented
Terminal elimination half-life: 1-1.5 hours in adults with normal renal function. In neonates, it is prolonged to 2-4 hours. In severe renal impairment (CrCl <20 mL/min), half-life extends up to 10-15 hours, requiring dose adjustment.
Clinical Note
moderateCeftazidime + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Ceftazidime."
Clinical Note
moderateCefotaxime + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Cefotaxime."
Clinical Note
moderateCeftazidime + Picosulfuric acid
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Ceftazidime."
Clinical Note
moderateCefotaxime + Picosulfuric acid
1.9 hours (range 1.5-2.8 hours); prolonged in renal impairment (up to 20 hours in ESRD).
Approximately 80-90% of the dose is excreted unchanged in the urine via glomerular filtration and tubular secretion. About 5-10% is excreted in bile and feces as desacetylcefotaxime, the active metabolite.
Primarily renal (80-90% unchanged via glomerular filtration), biliary/fecal <5%.
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefotaxime."